Senior Scientist
University of British Columbia, Canada
Greg Carney completed his doctorate in Pharmacology and Therapeutics, with a focus on pharmacoepidemiology at the University of British Columbia. His PhD thesis examined the comparative safety and effectiveness of medications commonly used to aid smoking cessation. Greg has worked for the Therapeutics Initiative since 2003, and is currently Co-Chair of the PharmacoEpidemiology Group (PEG). Greg has 20 years of experience in analysing health care databases to evaluate pharmaceutical policy and program changes, and in conducting drug safety and effectiveness studies. His current research focus is on the implementation and evaluation of physician audit and feedback programs using randomized designed delay trials.